pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker TVTX. Primary therapeutic focus areas include Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US HQ
2020 Founded
506 Employees
Public company Type
TVTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
RE-021 (Sparsentan)
Phase 2 · small molecule · Focal Segmental Glomerulosclerosis
RE-021 (Sparsentan) for Focal Segmental Glomerulosclerosis is a Phase 2 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code RET-D-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Travere Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Focal Segmental Glomerulosclerosis
- Status
- completed
- Trials
- 1